The fact that Novartis' drug is intended for first line use doesn't mean it has to be tested on criz naive patients. If that was directly from the article then it is confusing as Brigatinib is going after first line use but will have been tested on prior failure patients which is why the direct comparison between the two drugs isnt possible with Brigatinib obviously way ahead.
News 
Market Data 
Discover 
